Identifying key genetic regions that drive breast cancer growth and treatment resistance
Computational and experimental methods for scalable identification of oncogenic non-coding regions
This study is looking at how certain genes in your blood might help breast tumors grow and resist treatment, with the hope of finding new ways to fight breast cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11059881 on NIH RePORTER |
What this research studies
This research focuses on discovering specific genetic enhancers that play a crucial role in the growth of breast tumors and the development of resistance to treatments. By analyzing cell-free DNA from the blood of patients with metastatic breast cancer, the team will use advanced computational methods to identify these enhancers. The study aims to understand how these genetic regions influence tumor behavior and to explore the effects of manipulating them using CRISPR technology. This could lead to new strategies for targeting breast cancer more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic breast cancer who are experiencing treatment resistance.
Not a fit: Patients with early-stage breast cancer or those not diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer by targeting specific genetic factors that contribute to tumor growth and resistance.
How similar studies have performed: Other research has shown promise in using genetic manipulation techniques like CRISPR to target cancer-related genes, indicating potential success for this approach.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Khurana, Ekta — Weill Medical Coll of Cornell Univ
- Study coordinator: Khurana, Ekta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.